[ad_1]
Less than a week after Eisai and Biogen won accelerated approval from the FDA for their Alzheimer’s drug lecanemab, Executive Editor Drew Armstrong, Eisai’s U.S. CEO, announced the company’s commitment to Alzheimer’s disease. I spoke one-on-one with Ivan Cheung, who leads the effort. This transcript has been edited for brevity and clarity.
Drew Armstrong:
Welcome everyone. I’m Drew Armstrong, Executive His Editor at Endpoints News. Eisai is very pleased to have Ivan Cheung on board. He runs the US business and oversees Alzheimer’s disease programs there. Clearly, you all received the big news last week of the accelerated approval of lecanemab. Congratulations. It’s obviously a big moment for this space, and a big moment for your company, and I’d like to get started quickly, because it’s 30 minutes and a lot to cover. I am very much looking forward to this opportunity to speak with you. Well, I’m in San Francisco and you’re in New Jersey. I’m sorry that I can’t be with you directly, but I have a lot of news from everyone. You got this quick approval.
Requires a premium subscription
You can unlock this article and other perks by subscribing to one of our paid plans.
[ad_2]
Source link
